Predictive Value of Updating Framingham Risk Scores with Novel Risk Markers in the U.S. General Population by Ferket, Bart S. et al.
 
Predictive Value of Updating Framingham Risk Scores with Novel
Risk Markers in the U.S. General Population
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Ferket, Bart S., Bob J. H. van Kempen, M. G. Myriam Hunink,
Isha Agarwal, Maryam Kavousi, Oscar H. Franco, Ewout W.
Steyerberg, Wendy Max, and Kirsten E. Fleischmann. 2014.
“Predictive Value of Updating Framingham Risk Scores with
Novel Risk Markers in the U.S. General Population.” PLoS ONE 9
(2): e88312. doi:10.1371/journal.pone.0088312.
http://dx.doi.org/10.1371/journal.pone.0088312.
Published Version doi:10.1371/journal.pone.0088312
Accessed February 19, 2015 3:23:51 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879806
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAPredictive Value of Updating Framingham Risk Scores
with Novel Risk Markers in the U.S. General Population
Bart S. Ferket
1,2.", Bob J. H. van Kempen
1,2.", M. G. Myriam Hunink
1,2,3, Isha Agarwal
4,
Maryam Kavousi
1, Oscar H. Franco
1, Ewout W. Steyerberg
5, Wendy Max
6, Kirsten E. Fleischmann
7*
1Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands, 2Department of Radiology, Erasmus MC, Rotterdam, the Netherlands, 3Department of Health
Policy and Management, Harvard School of Public Health, Boston, Massachusetts, United States of America, 4Department of Epidemiology, Harvard School of Public
Health, Boston, Massachusetts, United States of America, 5Department of Public Health, Erasmus MC, Rotterdam, the Netherlands, 6Institute for Health & Aging and
Department of Social and Behavioral Sciences, University of California San Francisco, San Francisco, California, United States of America, 7Division of Cardiology,
University of California San Francisco, San Francisco, California, United States of America
Abstract
Background: According to population-based cohort studies CT coronary calcium score (CTCS), carotid intima-media
thickness (cIMT), high-sensitivity C- reactive protein (CRP), and ankle-brachial index (ABI) are promising novel risk markers
for improving cardiovascular risk assessment. Their impact in the U.S. general population is however uncertain. Our aim was
to estimate the predictive value of four novel cardiovascular risk markers for the U.S. general population.
Methods and Findings: Risk profiles, CRP and ABI data of 3,736 asymptomatic subjects aged 40 or older from the National
Health and Nutrition Examination Survey (NHANES) 2003–2004 exam were used along with predicted CTCS and cIMT values.
For each subject, we calculated 10-year cardiovascular risks with and without each risk marker. Event rates adjusted for
competing risks were obtained by microsimulation. We assessed the impact of updated 10-year risk scores by
reclassification and C-statistics. In the study population (mean age 56611 years, 48% male), 70% (80%) were at low (,10%),
19% (14%) at intermediate ($10–,20%), and 11% (6%) at high ($20%) 10-year CVD (CHD) risk. Net reclassification
improvement was highest after updating 10-year CVD risk with CTCS: 0.10 (95%CI 0.02–0.19). The C-statistic for 10-year CVD
risk increased from 0.82 by 0.02 (95%CI 0.01–0.03) with CTCS. Reclassification occurred most often in those at intermediate
risk: with CTCS, 36% (38%) moved to low and 22% (30%) to high CVD (CHD) risk. Improvements with other novel risk
markers were limited.
Conclusions: Only CTCS appeared to have significant incremental predictive value in the U.S. general population, especially
in those at intermediate risk. In future research, cost-effectiveness analyses should be considered for evaluating novel
cardiovascular risk assessment strategies.
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Introduction
Cardiovascular disease (CVD) remains the leading cause of
death in the U.S. population [1]. Current guidelines recommend
aggressive risk modifying treatment regimens in apparently
healthy individuals deemed to be at high cardiovascular risk [2].
These individuals can be identified using risk scores based on
traditional risk factors as defined by the Framingham Heart Study
[3,4]. However, the accuracy of Framingham risk scores (FRS) for
predicting CVD outcomes can be improved by adding novel risk
markers, including imaging techniques and biomarkers.
Recently, the U.S. Preventive Services Task Force and the
American College of Cardiology Foundation/American Heart
Association Task Force published recommendations on which
novel risk markers to use for cardiovascular risk assessment [5,6].
Four novel risk markers that are expected to have added predictive
value beyond the FRS are: the CT coronary artery calcium score
(CTCS), high-sensitivity C-reactive protein (CRP), the ankle-
brachial index (ABI) and measurement of carotid intima-media
thickness (cIMT). Most importantly, studies should have demon-
strated that risk assessment including these novel markers should
correctly reclassify individuals into clinically relevant risk catego-
ries. These risk categories are defined by 10-year risk: e.g. ,10%
(low risk), 10–19% (intermediate risk) and $20% (high risk).
Due to heterogeneous results [7–9] and selection of study
populations it remains difficult to generalize from published cohort
studies that adding these novel markers to the FRS would indeed
lead to improved classification in the U.S. population as a whole
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computer simulation modeling with data input from meta-analyses
combined with study data representative of the entire population
overcomes a number of these limitations [11].
In this study, we aimed to update traditional 10-year FRSs by
the published independent associations of CTCS, cIMT, CRP,
and ABI with cardiovascular events. Our final purpose was to
assess to what extent the predictive value of traditional risk
assessment would be improved by these four novel markers in
asymptomatic participants of the National Health and Nutrition
Examination Survey (NHANES), a cross-sectional study designed
to be a representative sample of the U.S. general population.
Methods
Systematic Review of the Novel Risk Markers’ Predictive
Effects
We adopted two recent individual-level meta-analyses for the
association of a one unit SD (1.11) log mg/L increase of CRP, and
the association of a 0.1 mm increase in mean cIMT with coronary
heart disease (CHD) and stroke event rates [12,13]. Both were
adjusted for traditional risk factors. For CTCS and ABI, we
updated the 2009 systematic review by the USPSTF [14] through
April 19, 2013 (for detailed search syntaxes and study inclusion
criteria see the Text S1). Two reviewers independently included
potentially eligible articles based on title and abstract. Only studies
that recruited subjects from the general population, and which
excluded or adjusted for prior CHD and stroke were included.
Articles were included if both reviewers agreed that the study
design was a cohort, nested case-control, or case-cohort study.
Also, systematic reviews that included these study types were
considered. Relative risk estimates had to be calculated for CHD
and/or stroke, with CHD defined as myocardial infarction or
coronary death. We excluded studies that analyzed the novel risk
marker with adjustment for less than 5 of the 8 Framingham risk
factors: age, sex, smoking, systolic blood pressure, antihypertensive
drug therapy, total cholesterol, high density (HDL) cholesterol and
diabetes mellitus. One reviewer extracted the reported relative
risks and 95% CI limits of an increase in 1 unit log (CTCS+1) for
CTCS, and of an ABI#0.90 vs. .0.90. If relative risks were
reported using other units, these were converted in order to match
the aforementioned units (see the Text S1 for details). Data
extraction was checked by a second reviewer. We used the R
‘meta.summaries’ function of the ‘rmeta’ package to compute
summary estimates and 95% CIs by random-effects modeling.
Heterogeneity was assessed statistically with the Woolf’s test where
values ,0.05 indicate significant heterogeneity.
Study Population
We selected data on 3,736 individuals aged 40 or older without
a history of myocardial infarction or stroke at baseline from the
2003–2004 NHANES exam, taking into account the sampling
weights. We used the following datasets: NHANES 2003–2004
Demographics Data, NHANES 2003–2004 Examination Data,
NHANES 2003–2004 Laboratory Data, and NHANES 2003–
2004 Questionnaire Data, see http://wwwn.cdc.gov/nchs/
nhanes/search/nhanes03_04.aspx. We included the following
variables: age at the exam visit, sex, current smoking, systolic
blood pressure, total cholesterol, HDL cholesterol, fasting plasma
glucose level, anti-diabetic treatment, antihypertensive treatment,
ankle-brachial index, and high-sensitivity C-reactive protein.
Because values for CTCS and cIMT were not measured in the
NHANES study, we merged the NHANES dataset with a subset of
the Rotterdam Study Cohort. The Rotterdam Study is a
population-based cohort study of individuals aged 55 years and
older living in Rotterdam, the Netherlands [15]. Baseline
examinations were performed between 1990 and 1993 (Rotterdam
Study-I). Traditional FRS risk factors, CTCS, cIMT, hs-CRP,
ABI, and information on cardioprotective drugs were simulta-
neously measured during the third examination round (1997 to
1999) in a subset (n=1,915) of the Rotterdam Study-I cohort.
Details on how these novel risk markers and the other variables
were measured are published elsewhere [16,17]. We imputed the
missing CTCS and cIMT values of NHANES subjects within the
merged dataset. For the imputation, we used a flexible additive
imputation model including all other variables. After the
imputation, only NHANES individuals were selected for the
analysis (see Table 1 for baseline characteristics, and Text S1 for
details on the dataset preparation.
Updating Framingham Risk Scores
For both the 10-year cardiovascular risk assessment and
simulation of event rates, we used the 30-year FRS as basis for
our models [18]. It uses the 8 aforementioned traditional risk
factors to calculate 30-year cumulative incidences for both CVD
and non-CVD deaths, while taking into account competing risks.
CVD is defined as myocardial infarction, coronary death and
stroke, non-CVD death is defined as mortality due to all causes
other than CVD. In order to calculate CHD and stroke risks
separately, we applied a sex-specific ratio of the reported CHD to
Table 1. Baseline characteristics of 3,736 NHANES and 1,915
Rotterdam Study individuals.
Variable
NHANES Median
[IQR] RS Median [IQR]
Age 53 [46–63] 70 [66–75]
Sex (%male) 48% 45%
Current Smoking 23% 16%
Systolic blood pressure
(mm Hg)
125 [115–139] 140.0 [124–155]
HRX 27% 28%
Total cholesterol (mg/dl) 209 [183–235] 225 [203–250]
HDL cholesterol (mg/dl) 51 [42–63] 51 [43–62]
Glucose (mg/dl) 97 [90–106] 99 [94–110]
Anti diabetic medication 8% 6.2%
CTCS*
0 37% 10%
1–100 36% 41%
101–400 14% 23%
400–1000 8% 15%
$1000 5% 11%
Natural logarithm of
(CTCS+1)
2.6 [0–4.8] 4.81 [2.6–6.3]
cIMT (mm)* 0.78 [0.69–0.93] 0.86 [0.76–0.95]
CRP (mg/L) 2.1 [0.9–4.6] 2.4 [1.2–4.4]
ABI#0.9 5.0% 15.6%
Abbreviations: CTCS, CT coronary artery calcium score; HDL, high-density
lipoprotein; HRX, antihypertensive drug treatment; NHANES, National Health
and Nutrition Examination Survey; RS, Rotterdam Study.
SI conversion factors: To convert CRP to nanomoles per liter, multiply by 9.524;
HDL and total cholesterol to millimoles per liter, multiply by 0.0259.
*Imputed by multivariable algorithms.
doi:10.1371/journal.pone.0088312.t001
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CHD: stroke event ratio was 348/104 and for women it was 133/
86. We assumed that the reported regression coefficients of the
traditional risk factors were similar for CHD and stroke. To
resemble currently recommended risk assessment, we calculated
10-year CVD and CHD risks without adjustment for competing
risk. We used the baseline CHD and CVD survival probability at
year 10 and subsequently updated the traditional FRS with one
novel risk marker at a time. We recalibrated the baseline survival
probability by assuming no change in the average survival
probability. For both 10-year CVD and CHD, the different
models (FRS only, FRS+CTCS, FRS+IMT, FRS+CRP, and
FRS+ABI) were used to classify the 3,673 NHANES subjects into
to the following risk categories: ,10%, $10–,20%, $20%. In
addition, we also classified into ,6%, $6–,20%, $20%:
categories [19].
Cardiovascular outcomes
To simulate cardiovascular event rates, we constructed a state-
transition model using TreeAge software (2009 version, TreeAge
Software, Inc., Williamstown, MA, USA), consisting of three
health states: ‘Well’, ‘Post-CVD’ and ‘Dead’ (see Table S1 for
input parameters). A one-year cycle length was used. One-year
transition-probabilities were based on the 30-year FRS updated
with all four novel risk markers together, assuming independency
of predictive effects. We recalibrated the baseline survival function
through 30 years of follow-up, while ascertaining that the average
30-year cumulative incidences for CVD and non-CVD death
calculated by the state-transition model were equal to the average
risks calculated by the original 30-year FRS for the NHANES
study sample (see the eMethods for details).
Predictive Value of the Four Updated Risk Scores
Reclassification tables were created by cross-tabulating
NHANES individuals using the three risk categories of the
traditional and each updated FRS. Occurrences of events within
these individuals were modeled through a state-transition model
using Monte Carlo microsimulation. We calculated risks in
subjects reclassified upwards and downwards for both cases and
non-cases and calculated the net reclassification improvement
(NRI) applicable to survival and competing risk data [20]. For the
intermediate risk category, we calculated a bias-corrected NRI
[21]. In addition, long-term 30-year risks were reported in the
reclassification tables to evaluate whether those who are reclassi-
fied have a long-term risk that is in agreement with the
reclassification. To further assess the models’ discriminative
performance, we calculated the Harrell’s C-statistic [22] using
simulated 10-year time-to-event data. To take into account the
uncertainty of the hazard ratios of the novel risk markers, 95% CIs
were calculated by randomly sampling from lognormal distribu-
tions defined by the summary estimates and standard errors taken
from the meta-analyses.
Ethics Statement
For the 2003–2004 NHANES, Institutional Review Board
(IRB) approval and documented consent was obtained from all
participants (Protocol #98-12). The Rotterdam Study has been
approved by the institutional review board (Medical Ethics
Committee) of the Erasmus Medical Center and by the review
board of The Netherlands Ministry of Health, Welfare, and
Sports. The approval has been renewed every 5 years.
Results
Systematic Review of the Novel Risk Markers’ Predictive
Effects
From the USPSTF report [14], eight studies on CTCS and ten
studies on ABI were included in our review. For ABI, we did not
use the reported estimates on CHD and stroke, because these were
based on a comparison between an ABI#0.9 and 1.11–1.40
instead of #0.9 vs. .0.9 [23]. Combined with the citations found
through our additional search, in total 1,107 citations were
included in our systematic review. Seventeen articles were used for
the data extraction; for reasons of exclusions see Figure 1. In 11 of
the articles the effect of the novel risk marker was adjusted for
seven or more Framingham risk factors (for the study details see
Table S2).
For the association between CTCS and CHD, we performed a
meta-analysis on a total of 30,945 individuals and 548 events.
Only two studies were found on the association of CTCS with
stroke, comprising 7,118 subjects and 117 stroke events. For the
ABI meta-analyses, 21,122 subjects with 1,206 CHD events and
36,941 subjects with 987 stroke events were used. One study on
the association between ABI and CHD also counted angina as a
CHD event [24]. As the authors explicitly stated that the analysis
limited to hard CHD events (i.e., excluding angina) showed similar
results, we included this study in the analysis. Summary estimates
from the meta-analyses are given in Table 2. We found no
statistical evidence for heterogeneity between studies. The forest
plots are included in the Figures S1, S2, S3, S4.
Predictive Value of the Four Updated Risk Scores
Most NHANES subjects were at low (,10%) 10-year CVD and
CHD risk: respectively 2,641 (71%) and 2,999 (80%). The number
of NHANES subjects with intermediate ($10–,20%) risk was
limited: 697 (19%) for CVD and 525 (14%) for CHD as the
outcome (see Table 3, and Tables S3 and S4). These numbers
approximately doubled with using the alternative threshold values
$6–,20% to 1385 (37%) for CVD and 1075 (29%) for CHD.
Amongst the updated models, the FRS+CTCS had the highest
NRI (Table 4). For the FRS updated with the other novel risk
markers, the reclassification was limited and the NRI was close to
zero for both CVD and CHD as end point (see Table 4 and Tables
S4 and S5). Net reclassification improvement results were similar
when using the ,6, $6–,20%, $20% risk categorization. The
number of high risk ($20%) individuals reclassified to lower risk
was limited –even for CTCS. Those who were reclassified upwards
had a much higher 30-year CVD and CHD risk than the risk for
those remaining in their risk category or who were reclassified
downwards (Table 3 and Table S4a).
Subjects who were traditionally classified as intermediate ($10–
,20%) 10-year CVD risk, were most frequently reclassified by
CTCS. In this intermediate risk category, 0.39 (95%CI 0.23–0.55)
of those with a CVD event within 10 years were reclassified
upwards, whereas only 0.17 (95%CI 0.09–0.27) were reclassified
downwards. For the subjects who did not experience an event,
0.37 (95%CI 0.35–0.39) were reclassified downwards and 0.18
(95%CI 0.11–0.25) upwards. The resulting bias-corrected NRI
from updating FRS by CTCS in the intermediate risk category
was 0.15 (95%CI 0.05–0.27). Defining $6–,20% as the
intermediate risk category, the bias-corrected NRI was 0.13
(95%CI 0.06–0.21). The C-statistic of the FRS increased most by
adding CTCS (Table 4 and Table S5). It increased from 0.82
(95%CI 0.79–0.85) to 0.84 (95%CI 0.81–0.86) for predicting CVD
and from 0.84 (95%CI 0.82–0.86) to 0.87 (95%CI 0.84–0.89) for
predicting CHD.
Impact of Novel Risk Markers in the U.S.
PLOS ONE | www.plosone.org 3 February 2014 | Volume 9 | Issue 2 | e88312Figure 1. Literature search and selection. Numbers of articles of each step of the review process are indicated. *Group total exceed the reported
number for the excluded articles because several reasons for exclusion were allowed. {Group total exceed the number for the included articles,
because one article may include estimates for both CHD and stroke. Abbreviations: ABI, ankle-brachial index; CHD, coronary heart disease; CTCS,
computed tomography calcium scoring; HR, hazard ratio; OR, odds ratio; RR, risk ratio; USPSTF, United States Preventive Services Task Force.
doi:10.1371/journal.pone.0088312.g001
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In this study, we modeled the predictive value of adding four
novel cardiovascular risk markers to traditional Framingham risk
scores (FRSs) in individuals representative of the U.S. general
population. Whereas previous studies have focused on the
predictive value of risk markers in specific longitudinal cohorts,
we aimed to study the potential value of using risk markers in the
US population as a whole. We used the two most commonly used
endpoints 10-year CVD and CHD risk, together with two
recommended risk categorization methods: ,10%, 10–19%,
$20% and ,6%, 6–19%, $20% for low, intermediate, and high
risk respectively. Among the four updated risk scores, the FRS
updated with CTCS showed the most impact on reclassification
for both CVD and CHD as endpoint, regardless of the risk
thresholds used. Most reclassification occurred in those tradition-
ally at intermediate risk; in other risk categories reclassification was
less evident. FRS updated by cIMT, CRP and ABI had limited
value with regard to appropriate reclassification and improvement
of the C-statistic.
Previous cohort studies have demonstrated the added predictive
value of CT coronary artery calcium score (CTCS), carotid
intima-media thickness (cIMT), high-sensitivity C-reactive protein
(CRP), and the ankle-brachial index (ABI) beyond FRS. The latter
three risk markers were recently evaluated in large individual-level
meta-analyses combining data from several cohort studies
[12,13,23,25]. Although the meta-analyses showed that these
markers are associated with CVD independently from Framing-
ham risk factors, the impact on improving risk prediction and
classification was generally limited. The meta-analysis evaluating
cIMT for 10-year CVD prediction showed similar C-statistics for
the FRS: 0.757, and FRS with addition of common cIMT: 0.759.
Only a small NRI: 0.008 was observed in the total population,
which increased to 0.036 in individuals at intermediate risk [13].
Table 2. Hazard Ratios and confidence intervals from the meta-analyses.
Novel risk marker HR [95% CI] for CHD HR [95% CI] for Stroke Source
Log(CTCS+1) 1.35 [1.28–1.43] 0.97 [0.84–1.12] This manuscript
0.1 mm IMT 1.08 [1.05–1.10] 1.12 [1.10–1.15] Den Ruijter et al. [13]
Log(CRP)/SD* (mg/L) 1.22 [1.17–1.27] 1.16 [1.10–1.27] Emerging Risk Factors Collaboration [12]
ABI#0.9 1.47 [1.18–1.84] 1.26 [1.05–1.50] This manuscript
*Pooled SD=1.11 mg/L.
doi:10.1371/journal.pone.0088312.t002
Table 3. Ten-year cardiovascular disease (CVD) risk reclassification by CTCS.
FRS+CTCS Overall
FRS ,10% $10–,20% $20%
,10%
N 2520.53 116.06 4.41 2641
% Events [ 95% CI ]
10 yr CVD 2.5 [1.9–3.2] 11.2 [6.1–16.6] 19.7 [0–85.8] 2.9 [2.3–3.5]
30 yr CVD 14.8 [13.0–16.2] 49.2 [39.8–57.3] 68.6 [0–100] 16.4 [15.0–18.0]
$10–,20%
N 240.28 309.36 147.36 697
% Events [ 95% CI ]
10 yr CVD 6.7 [3.5–9.6] 12.9 [9.0–16.4] 24.8 [17.7–31.4] 13.3 [10.8–16.0]
30 yr CVD 32.5 [27.0–38.9] 50.5 [45.5–55.9] 69.3 [60.9–77.6] 48.3 [43.6–51.9]
$20%
N 6.62 80.72 310.66 398
% Events [ 95% CI ]
10 yr CVD 9.7 [0–42.9] 13.9 [7.8–21.3] 40.3 [33.0–47.9] 34.4 [28.8–40.6]
30 yr CVD 33.7 [0–75.0] 48.4 [39.9–58.2] 74.1 [68.3–78.9] 68.2 [63.2–72]
Overall
N 2767.43 506.14 462.43 3736
% Events [ 95% CI ]
10 yr CVD 2.8 [2.3–3.5] 12.7 [9.6–15.4] 35.2 [30.0–40.0] 8.2 [7.3–40.0]
30 yr CVD 16.4 [14.8–17.8] 49.8 [45.0–54.3] 72.5 [67.6–76.7] 27.9 [26.3–76.7]
Classification on the basis of 10-year CVD risk assessment using ,10%, $10–,20%, and $20% as risk thresholds.
Abbreviations: CTCS, CT coronary artery calcium score.
doi:10.1371/journal.pone.0088312.t003
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Study data that showed similar results: a small change in the C-
statistic: 0.748 to 0.751 and 0.0 NRI. The meta-analysis on CRP
showed a change in the C-statistic of 0.0039, and the NRI was
0.0152 for CVD prediction. The Framingham Offspring data
included within the analysis showed that the C-statistic of 0.7779
increased by 0.0040. In the other included cohort studies, changes
in the C-statistic varied from 20.0027 to 0.0157 [25]. In the meta-
analysis on ABI, CHD risks were calculated after cross-tabulating a
FRS for predicting 10-yr CHD risk categories by four different ABI
categories.MeaningfulreclassificationbyABIwaslimitedtowomen
only: 7% of women at low risk and 10% of the women at
intermediate risk were reclassified as high risk based on an
ABI#0.90 [23]. Changes in the C-statistic and NRI with
ABI#0.90 have not been established. A recent study in the
Atherosclerosis Risk in Communities Study (ARIC Study) showed
only modest improvement in the C-statistic: 0.756 to 0.758 and a
NRI of 0.008 [26]. For CTCS, individual-level meta-analyses have
not yet been conducted, although a systematic review of cohort
studies shows that the impact on the C-statistic and NRI is generally
larger: changes in the C-statistic varied from 0.04 to 0.13 and NRIs
varied from 0.14 to 0.25 [9]. The four risk markers were evaluated
in a direct comparison by only two cohort studies: the Multi-Ethnic
Study of Atherosclerosis (MESA) and the Rotterdam Study [17,27].
Both studies concluded that among the four markers, CTCS has the
most added value in those at intermediate risk. In MESA, addition
of CTCS, cIMT, CRP or ABI to a FRS plus race/ethnicity led to
NRIs of 0.659, 0.102, 0.079, and 0.036 respectively. In the
Rotterdam Study, these were 0.393, 0.046, 0.092, and 0.073. These
NRIs were, however, not bias-corrected [21].
Generalizing results on reclassification from cohort studies to the
generalpopulationis not straightforward. The impact ofa novel risk
marker on improving risk classification is determined by the
strength of the association with the outcome, but also depends on
the joined distribution of the marker and traditional risk factors in
thepopulation[10].Because the distributionofriskfactorsincohort
studies is not comparable to the general population, we reproduced
cardiovascular risk predictions by Framingham risk factors and
novel risk markers within a recent NHANES sample while
hypothesizing that these are generalizable. Although we were able
to apply the summarized independent associations of novel risk
markers with CVD to the NHANES sample, our study bears some
important limitations. First, the NHANES did not include
measurements of CTCS and cIMT. We therefore had to impute
these measurements. We used correlations between Framingham
risk factors and the other two novel risk markers as observed in the
Rotterdam Study for the imputation process. Thus, the CTCS and
cIMT values were distributed in the NHANES subjects condition-
ally on the assumption that the correlations in the Rotterdam Study
are applicable to the NHANES population. Second, the NHANES
data do not include CVD event rates and we therefore had to
assume that the FRS [18] would be valid for the NHANES
population in predicting event rates. However, it has been shown
that Framingham-based predictions perform fairlywell in most U.S.
subpopulations [28]. Third, for the simulation of CVD event rates,
we assumed that the associations of the four novel risk markers with
CVD were independent of each other. Few studies published the
change in hazard ratios of these novel risk markers after
subsequently adding them to the FRS. Generally, the amount of
confounding is limited [29]. Fourth, because our purpose was to
evaluate the additional value of novel risk markers in the light of
competing risk by non-CVD death, we chose a FRS that took into
account the competing risk of non-CVD death for our simulation
model. This FRS however uses total CVD as outcome and does not
allow associations of traditional risk factors to be different for CHD
and stroke events [3]. We therefore hypothesized that these effects
would be similar. Although this seems to be a reasonable
assumption for the most important cardiovascular risk factors -age
and sex, this may be less true for other risk factors suchas lipid levels
[30]. However, CHD comprises the major part of total CVD. This
implies that the associations of the traditional risk factors with CVD
are closer to that of CHD than of stroke, and the results for
reclassification of CHD will be relatively unaffected by this
assumption. Finally, putting CHD and stroke and under the same
term might be problematic when the goal is to individualize
predictions while considering the difference in pathophysiology. For
example, cIMT might well improve predictions of future stroke but
not CHD. A separate assessment of stroke risk is generally however
not advocated by most guideline groups, and we therefore did not
evaluate a potential improvement of stroke prediction [31].
Instead of a priori focusing on individuals at intermediate risk
[14,27], we also included low and high-risk individuals. In theory,
reclassifying high-risk individuals without events downwards could
be beneficial as well. However, we demonstrated that CTCS has
the largest value in refining decision-making in the intermediate
risk category. Reclassification of subjects originally at low or high
risk was much more limited. The size of the U.S. general
population considered to be at intermediate risk largely depends
Table 4. Predictive value of novel risk markers for 10-year cardiovascular disease.
FRS+CTCS FRS+cIMT FRS+CRP FRS+ABI
D C-statistic vs. FRS [95%CI] 0.02 [0.01–0.03] 0.00 [0.00–0.01] 0.00 [0.00–0.01] 0.00 [0.00–0.00]
NRI with ,10%, $10–,20%, and $20%
NRI|event [ 95%CI ] 0.07 [20.02–0.17] 0.00 [20.02–0.03] 0.01 [20.02–0.05] 20.01 [20.04–0.02]
NRI|no event [ 95%CI ] 0.02 [0.00–0.05] 0.01 [0.01–0.01] 0.00 [0.00–0.01] 0.01 [0.01–0.01]
NRI total [ 95%CI ] 0.10 [0.02–0.19] 0.01 [20.01–0.04] 0.01 [20.02–0.05] 0.00 [20.03–0.03]
NRI with ,6%, $6–,20%, and $20%
NRI|event [ 95%CI ] 0.06 [20.03–0.15] 20.01 [20.03–0.02] 0.00 [20.03–0.04] 20.01 [20.03–0.01]
NRI|no event [ 95%CI ] 0.07 [0.05–0.09] 0.03 [0.03–0.03] 0.02 [0.01–0.02] 0.01 [0.01–0.01]
NRI total [ 95%CI ] 0.13 [0.05–0.22] 0.02 [20.01–0.05] 0.02 [20.01–0.06] 0.00 [20.02–0.02]
Abbreviations: ABI, ankle-brachial index; cIMT, carotid intima-media thickness; CRP, high-sensitivity C-reactive protein; C-statistic, Harrell’s concordance index; CTCS,
CT coronary artery calcium score; FRS, Framingham risk score; NRI, net reclassification improvement.
doi:10.1371/journal.pone.0088312.t004
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impact of additional testing with novel risk markers to decrease the
total number of events will vary with this definition. Its impact will
also depend on the indirect association of the novel risk marker
with competing non-CVD death, e.g. through a strong correlation
with age. There is, however, no indication that those reclassified to
high risk suffer from a larger risk of competing death as
demonstrated by a concordant increase in long-term, 30-year
risk. Ultimately, costs and effects of recommended preventive
treatment on quality-adjusted life expectancy should be considered
for evaluating the impact of novel cardiovascular risk assessment
strategies [32].
In conclusion, among four promising novel risk markers, only
CTCS is expected to have significant incremental predictive value
in the U.S. general population, and especially in those at
intermediate risk. Future research should be performed to evaluate
the clinical impact and cost-effectiveness of various novel
cardiovascular risk assessment strategies.
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